A 'surprising' Phase III knocks back AstraZeneca, Amgen's blockbuster asthma ambitions
Two months have brought two very different results for Amgen, AstraZeneca and their blockbuster-potential asthma drug.
The companies announced Tuesday that the drug — a once-a-month antibody infusion called tezepelumab — failed in a Phase III trial on severe asthma patients, clouding the pivotal win they announced last month in the same patient population.
Although it involved the same type of patients, the new trial crucially measured different outcomes. While the positive Phase III tested measured reduction in asthma attacks against placebo plus standard of care, the new one tested to see whether the drug reduced the number of oral corticosteroids patients took to control their asthma.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.